These longitudinal experiments revealed more than forty proteins that were dysregulated during GBM development, several of which have previously been reported as candidate diagnostic biomarkers (Vtn, Flna, C1qa, and Gsn) or prognostic biomarkers (Ahsg). This evidence concerns the gene GSN and glioblastoma.